To hear about similar clinical trials, please enter your email below
Trial Title:
Biomolecular Analysis for Predicting Response to Regorafenib
NCT ID:
NCT05759195
Condition:
Glioblastoma
Glioblastoma, IDH-wildtype
Conditions: Official terms:
Glioblastoma
Conditions: Keywords:
regorafenib
NGS
predictive biomarker
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Other
Masking:
None (Open Label)
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
Biomolecular tumor analysis
Description:
NGS analysis, other molecular analyses on FFPE tumor tissue
Arm group label:
Biomolecular tumor analysis
Summary:
The study envisages NGS analysis on tumor tissue from patients treated with regorafenib
for recurrent glioblastoma as per standard care, with the aim to identify predictive
biomarkers for response.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. recurrent glioblastoma after surgery and chemoradiation with temozolomide;
2. indication to treatment with regorafenib per standard of care;
3. written informed consent.
Exclusion Criteria:
None.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Fondazione Policlinico Universitario A. Gemelli IRCCS
Address:
City:
Rome
Zip:
00168
Country:
Italy
Status:
Recruiting
Investigator:
Last name:
Q. Giorgio D'Alessandris, MD
Email:
Principal Investigator
Start date:
January 7, 2021
Completion date:
December 31, 2024
Lead sponsor:
Agency:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Agency class:
Other
Source:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05759195
